Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatmentNew translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KR…